{"created":"2021-03-01T06:12:46.842443+00:00","id":8746,"links":{},"metadata":{"_buckets":{"deposit":"a7ffcf3a-7f2a-4d91-9cdf-48ed03850aeb"},"_deposit":{"id":"8746","owners":[],"pid":{"revision_id":0,"type":"depid","value":"8746"},"status":"published"},"_oai":{"id":"oai:niigata-u.repo.nii.ac.jp:00008746","sets":["453:456","471:537:538:913"]},"item_7_alternative_title_1":{"attribute_name":"その他のタイトル","attribute_value_mlt":[{"subitem_alternative_title":"Evaluation of Serum Trough Levels After Oral Administration of High Dose Levofloxacin in Japanese Homedialysis Patients"}]},"item_7_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2015-03","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"3","bibliographicPageEnd":"112","bibliographicPageStart":"105","bibliographicVolumeNumber":"129","bibliographic_titles":[{"bibliographic_title":"新潟医学会雑誌"},{"bibliographic_title":"新潟医学会雑誌","bibliographic_titleLang":"en"}]}]},"item_7_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"これまで使用されてきたLevofloxacin(LVFX)低用量(100mg)製剤に変わって, 2009年に発売された500mg, 250mg製剤の日本人透析患者における血中濃度, 安全性を検討した報告は少ないため, 感染症治療のためにLVFXを使用した透析患者に対し, 透析前血中トラフ濃度の測定を行い, 血液透析患者における血中濃度を確認した. 今回9症例を登録し解析した. 全例LVFXで感染症の症状は軽快していた. 全症例の平均血中トラフ値は3.46±1.42μg/mlであった. 500mg単回投与で投与後二日目の透析直前の平均が4.18±1.35μg/mlで, 透析間隔の関係により72時間時点で採血した症例では2.93であった. また, 複数回投与症例においても最終投与後48時間での血中濃度トラフ値は平均2.17±0.72μg/mlと複数回投与でも薬剤の蓄積傾向はなかった. 一方で体重と血中濃度のトラフ値には単回投与群で明確な相関がみられた. LVFX500mg錠発売後, 多くの透析患者での使用実績があり透析患者においても重篤な有害事象の報告は少なく安全に使用できる薬剤であるが, 透析患者では高齢者, 低体重患者も多くPK-PD上の至適用量として減量が可能な症例の有無等さらなるデータ蓄積が望まれる.","subitem_description_type":"Abstract"}]},"item_7_full_name_3":{"attribute_name":"著者別名","attribute_value_mlt":[{"nameIdentifiers":[{"nameIdentifier":"60989","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Cho, Hiromi"}]},{"nameIdentifiers":[{"nameIdentifier":"60990","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Narita, Ichiei"}]}]},"item_7_publisher_7":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"新潟医学会"}]},"item_7_select_19":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_select_item":"publisher"}]},"item_7_source_id_11":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AN00182415","subitem_source_identifier_type":"NCID"}]},"item_7_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"00290440","subitem_source_identifier_type":"ISSN"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"張, 仁美"}],"nameIdentifiers":[{"nameIdentifier":"60987","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"成田, 一衛"}],"nameIdentifiers":[{"nameIdentifier":"60988","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2019-08-06"}],"displaytype":"detail","filename":"129(3)_105-112.pdf","filesize":[{"value":"2.2 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"129(3)_105-112.pdf","url":"https://niigata-u.repo.nii.ac.jp/record/8746/files/129(3)_105-112.pdf"},"version_id":"0eccee7c-9703-4edd-ae03-4074b3eb6e15"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"LVFX","subitem_subject_scheme":"Other"},{"subitem_subject":"血液透析","subitem_subject_scheme":"Other"},{"subitem_subject":"血中トラフ濃度","subitem_subject_scheme":"Other"},{"subitem_subject":"PK-PD","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"日本人血液透析患者に対するレボフロキサシン500mg投与後の血中濃度の検討","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"日本人血液透析患者に対するレボフロキサシン500mg投与後の血中濃度の検討"},{"subitem_title":"日本人血液透析患者に対するレボフロキサシン500mg投与後の血中濃度の検討","subitem_title_language":"en"}]},"item_type_id":"7","owner":"1","path":["456","913"],"pubdate":{"attribute_name":"公開日","attribute_value":"2016-09-27"},"publish_date":"2016-09-27","publish_status":"0","recid":"8746","relation_version_is_last":true,"title":["日本人血液透析患者に対するレボフロキサシン500mg投与後の血中濃度の検討"],"weko_creator_id":"1","weko_shared_id":null},"updated":"2022-12-15T03:43:03.305312+00:00"}